The TEPEZZA OBI trial evaluated the safety and efficacy of SC teprotumumab in patients with active TED and proptosis of 3mm or greater from baseline.

Basel, 14 November 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of ...

Sanofi’s Sarclisa subcutaneous formulation administered via on-body injector recommended for EU approval by the CHMP to treat multiple myeloma Recommendation based on positive results demonstrating ...

Ocrevus Zunovo is the first and only biannual professional-administered ~10 min SC injection approved for both forms of multiple sclerosis. The subcutaneous formulation of Tecentriq received its first ...

LEQEMBI IQLIK is the first and only anti-amyloid treatment to offer an at-home injection to help patients and care partners continue to treat this progressive, relentless disease after initial ...

Positive opinion granted for SC administration of KEYTRUDA for all adult indications approved in the European Union for KEYTRUDA Positive opinion also granted for KEYTRUDA as part of a perioperative ...

Tuesday, the European Commission approved Roche Holdings AG’s (OTC:RHHBY) Tecentriq SC (atezolizumab), the European Union (EU) ‘s first PD-(L)1 cancer immunotherapy for subcutaneous (under the skin) ...

Overcoming common challenges with today’s biologics, such as developing devices for high-concentration subcutaneous ...

In the final episode, Overcoming Barriers and Future Integration of Subcutaneous Therapies in Lung Cancer, the panelists ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the Center for Drug Evaluation (CDE) of the China National Medical Products Administration ...